Celularity Inc. (NASDAQ:CELU) shares traded 9.57% higher at $0.38 on Wall Street last session.
In accordance with the data, 1 analysts cover Celularity Inc. (NASDAQ:CELU). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $2.50 and a low of $2.50, we find $2.50. Given the previous closing price of $0.35, this indicates a potential upside of 614.29 percent. CELU stock price is now -36.80% away from the 50-day moving average and -62.62% away from the 200-day moving average. The market capitalization of the company currently stands at $63.96M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $2.50 as their price target over the next twelve months.
With the price target reduced from $5 to $1, Morgan Stanley Downgraded its rating from Equal-Weight to Underweight for Celularity Inc. (NASDAQ: CELU).
In other news, Hariri Robert J, Chief Executive Officer bought 10,000 shares of the company’s stock on Nov 30. The stock was bought for $17,175 at an average price of $1.72. Upon completion of the transaction, the Chief Executive Officer now directly owns 8,074,996 shares in the company, valued at $3.07 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 29, Chief Executive Officer Hariri Robert J bought 40,000 shares of the business’s stock. A total of $68,400 was incurred on buying the stock at an average price of $1.71. This leaves the insider owning 8,064,996 shares of the company worth $3.06 million. Insiders disposed of 44,694 shares of company stock worth roughly $16983.72 over the past 1 year. A total of 6.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CELU stock. A new stake in Celularity Inc. shares was purchased by GLADIUS CAPITAL MANAGEMENT LP during the first quarter worth $16,000. Y-INTERCEPT (HONG KONG) LTD invested $16,000 in shares of CELU during the first quarter. In the first quarter, PRUDENTIAL FINANCIAL INC acquired a new stake in Celularity Inc. valued at approximately $15,000. GSA CAPITAL PARTNERS LLP acquired a new stake in CELU for approximately $7,000. KESTRA ADVISORY SERVICES, LLC purchased a new stake in CELU valued at around $7,000 in the second quarter. In total, there are 83 active investors with 24.40% ownership of the company’s stock.
Celularity Inc. (NASDAQ: CELU) opened at $0.3448 on Thursday. During the past 12 months, Celularity Inc. has had a low of $0.34 and a high of $3.69. As of last week, the company has a debt-to-equity ratio of 0.23, a current ratio of 0.40, and a quick ratio of 0.30. The fifty day moving average price for CELU is $0.6035 and a two-hundred day moving average price translates $1.0175 for the stock.
The latest earnings results from Celularity Inc. (NASDAQ: CELU) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.41, missing analysts’ expectations of -$0.24 by -0.17. This compares to -$0.48 EPS in the same period last year. The net profit margin was 81.60% and return on equity was 7.80% for CELU. The company reported revenue of $3.94 million for the quarter, compared to $5.93 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -33.7 percent. For the current quarter, analysts expect CELU to generate $26.8M in revenue.
Celularity Inc.(CELU) Company Profile
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company’s lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin’s lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products. The company was founded in 1998 and is based in Florham Park, New Jersey.
